EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy - 19/06/14
, Robin Boineau, MD, MA b, j, Christine Goertz, DC, PhD c, j, Daniel B. Mark, MD, MPH i, j, Yves Rosenberg, MD b, j, Mario Stylianou, PhD b, j, Theodore Rozema, MD d, j, Richard L. Nahin, PhD, MPH e, j, L. Terry Chappell, MD f, j, Lauren Lindblad, MS i, j, Eldrin F. Lewis, MD g, j, Jeanne Drisko, MD h, j, Kerry L. Lee, PhD i, jRésumé |
Background |
Disodium ethylenediaminetetraacetic acid (EDTA) reduced adverse cardiac outcomes in a factorial trial also testing oral vitamins. This report describes the intent-to-treat comparison of the 4 factorial groups overall and in patients with diabetes.
Methods |
This was a double-blind, placebo-controlled, 2 × 2 factorial multicenter randomized trial of 1,708 post–myocardial infarction (MI) patients ≥50 years of age and with creatinine ≤2.0 mg/dL randomized to receive 40 EDTA chelation or placebo infusions plus 6 caplets daily of a 28-component multivitamin-multimineral mixture or placebo. The primary end point was a composite of total mortality, MI, stroke, coronary revascularization, or hospitalization for angina.
Results |
Median age was 65 years, 18% were female, 94% were Caucasian, 37% were diabetic, 83% had prior coronary revascularization, and 73% were on statins. Five-year Kaplan-Meier estimates for the primary end point was 31.9% in the chelation + high-dose vitamin group, 33.7% in the chelation + placebo vitamin group, 36.6% in the placebo infusion + active vitamin group, and 40.2% in the placebo infusions + placebo vitamin group. The reduction in primary end point by double active treatment compared with double placebo was significant (hazard ratio 0.74, 95% CI 0.57-0.95, P = .016). In patients with diabetes, the primary end point reduction of double active compared with double placebo was more pronounced (hazard ratio 0.49, 95% CI 0.33-0.75, P < .001).
Conclusions |
In stable post-MI patients on evidence-based medical therapy, the combination of oral high-dose vitamins and chelation therapy compared with double placebo reduced clinically important cardiovascular events to an extent that was both statistically significant and of potential clinical relevance.
Le texte complet de cet article est disponible en PDF.Plan
| Guest Editor: Robert A. Harrington, MD, served as guest editor for this article |
Vol 168 - N° 1
P. 37 - juillet 2014 Retour au numéro
Article précédent
- Rationale and design of PRIMA II: A multicenter, randomized clinical trial to study the impact of in-hospital guidance for acute decompensated heart failure treatment by a predefined NT-PRoBNP target on the reduction of readmIssion and Mortality rAtes
- Susan Stienen, Khibar Salah, Andreas H.M. Moons, Adrianus L.M. Bakx, Petra E. van Pol, Jutta M. Schroeder-Tanka, Albertus J. Voogel, Jan T. Keijer, R.A. Mikael Kortz, Cathelijne Dickhoff, Paola G. Meregalli, Jan G. Tijssen, Yigal M. Pinto, Wouter E. Kok
- A metabolomic profile is associated with the risk of incident coronary heart disease
- Anika A.M. Vaarhorst, Aswin Verhoeven, Claudia M. Weller, Stefan Böhringer, Sibel Göraler, Axel Meissner, André M. Deelder, Peter Henneman, Anton P.M. Gorgels, Piet A. van den Brandt, Leo J. Schouten, Marleen M. van Greevenbroek, Audrey H.H. Merry, W.M. Monique Verschuren, Arn M.J.M. van den Maagdenberg, Ko Willems van Dijk, Aaron Isaacs, Dorret Boomsma, Ben A. Oostra, Cornelia M. van Duijn, J. Wouter Jukema, Jolanda M.A. Boer, Edith Feskens, Bastiaan T. Heijmans, P. Eline Slagboom
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?